At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic has posed a
huge threat to global health because of its rapid spread and various mutant variants. Critical …

SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …

Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …

Background Patients on therapeutic immunosuppressants for immune-mediated
inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Background People living with HIV might have a poor or delayed response to vaccines,
mainly when CD4 cell counts are low, and data concerning COVID-19 vaccines in this …

Importance To our knowledge, little is known about antibody development after SARS-CoV-
2 vaccination in immunocompromised individuals, such as patients with cancer. Objective …

Although universal vaccination is one of the most important healthcare strategies for limiting
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) circulation and averting the …

This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-
nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or …